Slower Nutrition And Diagnostics Weighed On Abbott In Q1; What To Watch For Q2

Source and reference

source on Google Add Now Abbott ( ABT ) will report second-quarter 2026 financial results on Thursday, July 16, 2026, before the market opens, with investors focused on whether momentum in Medical Devices and the newly added oncology diagnostics business can offset lingering softness in Nutrition and Rapid/Molecular Diagnostics. Q1 2026 vs. Q1 2025: Growth Driven by Devices and Exact Sciences Acquisition For the first quarter ended March 31, 2026, Abbott reported net sales of $11.16 billion, up 7.8% from $10.36 billion in Q1 2025. Comparable sales grew 3.7%, reflecting underlying performance excluding FX and the Exact Sciences acquisition impact. Adjusted diluted EPS was $1.15, up 6% from $1.09 in Q1 2035. GAAP EPS declined to $0.61 from $0.76 due to higher operating costs and acquisition-related expenses. Segment Performance: • Medical Devices delivered strong growth, with sales...